# A Study to Test the Safety and Effectiveness of GSK5764227, Alone or With Other Treatments, in Participants With Advanced Gastrointestinal Cancers That Cannot be Surgically Removed (EMBOLD PanGI-201)

Source: https://onco.cc/trials/nct06885034/  
OnCo record `nct06885034` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of Risvutatug Rezetecan in advanced solid tumours, run by GlaxoSmithKline, now recruiting.

## Summary

A Study to Test the Safety and Effectiveness of GSK5764227, Alone or With Other Treatments, in Participants With Advanced Gastrointestinal Cancers That Cannot be Surgically Removed (EMBOLD PanGI-201) is a phase 1/2 interventional study registered as NCT06885034 by GlaxoSmithKline, with 451 participants planned, started 2025-06-11 and due to reach its primary completion in 2028-01-10. Interventions recorded: Risvutatug Rezetecan, Drug 1, Drug 2, Drug 3 and Drug 4.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06885034
- Phase: 1/2
- Setting: A Phase1 b/2, Multicenter, Open-label Study to Evaluate the Efficacy and Safety of GSK5764227 Alone and in Combination in Participants With Previously Treated Advanced Unresectable or Metastatic Gastrointestinal Solid Tumors
- Sponsor: GlaxoSmithKline
- Enrolled: 451

## Sources

- ClinicalTrials.gov NCT06885034: https://clinicaltrials.gov/study/NCT06885034

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)
- companies: [GSK](https://onco.cc/companies/gsk/)

---
JSON: https://onco.cc/api/v1/entities/nct06885034.json